Pfizer and BioNTech climb as 95% vaccine effectiveness tees up application for FDA approval

Pfizer and Bio-Ntech, the world’s leading pharmaceutical companies, said on Wednesday that their Kovid-19 vaccine was found to be up to 95 percent effective in the final analysis of the Phase III trial. It also works for people over 65 years of age.

With this, these companies can apply for an emergency approval from the US regulator. The US pharma company and its German partner Bio-Entech said that they had completed the Phase III study of Kovid-19’s mRNA-based potential vaccine ‘BNT162B2’ in which they had all initial effects. Based on current estimates, companies are expected to produce 50 million doses of the vaccine globally by 2020.

The company’s production could reach 130 million doses by the end of 2021. Two days before this, the Moderna company announced that the vaccine produced by it is 94.5 percent effective. Analysis of the data, according to Pfizer and Bio-Entech, showed that the potential vaccine is up to 95 percent effective in participants who did not develop coronavirus infection.

Potential vaccine effects were also seen in those who were infected. The test was conducted seven days after the second dose was given to the participants. The companies said the first analysis was based on 170 cases of Kovid-19, of which 162 cases of infection were from the ‘placebo’ group and eight from the ‘BNT 162B2’ group.

He said that the potential vaccine proved effective on people of all ages, sexes and ethnicities and it was found to be up to 94 percent effective on people above 65 years. Dr. Albert Burla, President and Chief Executive Officer of Pfizer said, “The results of this study have marked a significant breakthrough in the eight-month journey.

We are engaged in the manufacture of vaccines to end this deadly epidemic. We are following the pace of science and are sharing all the data collected so far with regulators around the world. ” “Hundreds of people are getting infected every day in the world and we urgently need an effective vaccine,” he said.

Pfizer and Bio-Entech will soon send proposals to the US Food and Drug Administration (FDA) for vaccine approval.